Social Networks and Life Science Companies: Balancing Regulation and Risk Aversion with Opportunity

JANE SARASOHN-KAHN

Originally published here on 12/15/10 on Health Populi.

One in 3 managers in life science companies — including biotech, pharma, medical device and diagnostics firms — have no plans to engage with online social networks, according to a survey conducted by Deloitte. The key reasons for shying away from social networks include lack of guidelines offered by the Food & Drug Administration (FDA), concerns about consumer privacy, and low or uncertain return on investment.

Continue reading “Social Networks and Life Science Companies: Balancing Regulation and Risk Aversion with Opportunity”

The Social Life of Pharmaceutical Companies

JANE SARASOHN-KAHN

Originally published on 12/07/10 on Health Populi here.

Exactly one year ago, health care companies, online portals (from Google to health advocacy sites), and advertising agencies serving the health industry convened in Washington, DC, to voice their positions to the Food & Drug Administration (FDA) concerning pharmaceutical promotion and social media. It was such a monumental meeting that a tweetstream was initiated at the event that has been ongoing for the past year at #FDASM on Twitter.

Continue reading “The Social Life of Pharmaceutical Companies”